Article
Behavioral Sciences
Yuan Shen, Haicun Shi, JianGuo Zhong, PingLei Pan, ShuFang Wang, MingZhu Chen, ZhiPeng Chen, ChunFeng Liu
Summary: This study aimed to explore the factors correlated with excessive daytime sleepiness (EDS) in patients with Parkinson's disease (PD). The findings revealed that fatigue and respiratory-related microarousal index were independent risk factors for EDS in PD patients. Fragmented sleep and pathological abnormalities of the central nervous system resulting in changes in arousal are speculated to be major influencing factors of EDS in PD.
BRAIN AND BEHAVIOR
(2023)
Article
Clinical Neurology
Jean-Christophe Corvol, Jean-Philippe Azulay, Bjorn Bosse, Yves Dauvilliers, Luc Defebvre, Fabian Klostermann, Norbert Kovacs, David Maltete, William G. Ondo, Rajesh Pahwa, Werner Rein, Stephane Thobois, Martin Valis, Aleksandar Videnovic, Olivier Rascol
Summary: The study of THN102 in PD patients with EDS showed that the 200/2 dose demonstrated efficacy and good tolerability, supporting further development. On the other hand, the 200/18 dose did not show significant improvement.
MOVEMENT DISORDERS
(2022)
Article
Clinical Neurology
Keitaro Ogaki, Hiroaki Fujita, Narihiro Nozawa, Tomohiko Shiina, Hirotaka Sakuramoto, Keisuke Suzuki
Summary: The study aimed to identify the contributors to sleep disturbances, including insomnia, restless legs syndrome, rapid eye movement sleep behavior disorder (RBD), sleep-disordered breathing, nocturnal akinesia and excessive daytime sleepiness (EDS), in patients with Parkinson's disease (PD). The results showed that autonomic symptoms were associated with sleep disturbances or EDS, and depressive and RBD symptoms in addition to autonomic symptoms were associated with both sleep disturbances and EDS in patients with PD.
FRONTIERS IN NEUROLOGY
(2023)
Article
Behavioral Sciences
Marco Gallazzi, Marco Mauri, Maria Laura Bianchi, Giulio Riboldazzi, Lucia Princiotta Cariddi, Federico Carimati, Valentina Rebecchi, Maurizio Versino
Summary: The study found that the use of selegiline improved excessive daytime sleepiness in Parkinson's disease patients significantly, but did not change the evaluation of disease severity. Therefore, selegiline may be a valuable add-on therapy to reduce daytime somnolence in PD patients.
BRAIN AND BEHAVIOR
(2021)
Article
Clinical Neurology
Xiaoying Zhang, Sheng Zhuang, Jiajing Wu, Lanxiang Wang, Chengjie Mao, Jing Chen, Chun-feng Liu
Summary: Low frequency rTMS over right DLPFC may improve symptoms of excessive daytime sleepiness in Parkinson's disease patients. This study provides new possibilities for the treatment of EDS.
Article
Geriatrics & Gerontology
Lixia Zhang, Yajing Chen, Xiaoniu Liang, Lan Wang, Jian Wang, Yilin Tang, Xiaodong Zhu
Summary: This study compares the quality of life between Parkinson's disease patients with and without excessive daytime sleepiness (EDS) and investigates the impact of clinical factors on quality of life. The results show that patients with EDS have poorer quality of life and more non-motor symptoms.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Clinical Neurology
Yezhou Li, Jing Wang, Lirong Ji, Chaohong Cheng, Tong Su, Shuqing Wu, Fei Han, Daniel J. Cox, Erlei Wang, Rui Chen
Summary: This study aims to investigate the effects of excessive daytime sleepiness on cortical thickness in patients with obstructive sleep apnoea. It was found that the cortical thickness was significantly thinner in the sleepiness group, particularly in the left temporal, frontal, and parietal lobe, and bilateral pre- and postcentral gyri. There was a significant negative correlation between the cortical thickness and the Epworth Sleepiness Scale score.
FRONTIERS IN NEUROLOGY
(2023)
Review
Clinical Neurology
Fei Feng, YingYing Cai, YanBing Hou, Ruwei Ou, Zheng Jiang, HuiFang Shang
Summary: The study found that approximately one-third of patients with Parkinson's disease (PD) had excessive daytime sleepiness (EDS), which may be associated with the severity of the disease, depression symptoms, male sex, and medication.
PARKINSONISM & RELATED DISORDERS
(2021)
Article
Geriatrics & Gerontology
Cihan Heybeli, Pinar Soysal, Mehmet Asi Oktan, Lee Smith, Ali Celik, Rumeyza Kazancioglu
Summary: Excessive daytime sleepiness (EDS) is associated with malnutrition in older patients with chronic kidney disease (CKD), highlighting the importance of evaluating EDS and nutritional status together in clinical practice. Future studies are needed to determine the direction of the association between malnutrition and EDS and to evaluate if dietary intervention can improve EDS.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Article
Clinical Neurology
Octavian Adam, Sharmeen Azher, Edward Valachovic, Amy Hahn, Eric Molho
Summary: This study aimed to investigate the association between the HLA risk allele DQB1*0602 and excessive daytime sleepiness (EDS) in patients with Parkinson's disease (PD). The results showed that PD patients with the DQB1*0602 allele were more likely to experience EDS and inappropriate sleep during activities that require sustained alertness. Genetic vulnerability may play a role in explaining the risk of EDS in PD patients.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Yang Hu, Peng Guo, Teng-Hong Lian, Li-Jun Zuo, Shu-Yang Yu, Li Liu, Zhao Jin, Qiu-Jin Yu, Rui-Dan Wang, Li-Xia Li, Ying-Shan Piao, Wei Zhang
Summary: The study found that excessive daytime sleepiness is a common symptom in patients with Parkinson's disease, which is associated with more severe motor and non-motor symptoms, and overloaded iron-relevant inflammation in the brain might be an underlying mechanism of PD-EDS.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Clinical Neurology
Ming Liu, Ya-Jun Luo, Han-Ying Gu, Yi-Ming Wang, Man-Hua Liu, Kai Li, Jiao Li, Sheng Zhuang, Yun Shen, Hong Jin, Jing Chen, Cheng-Jie Mao, Chun-Feng Liu
Summary: Gender and age at onset have an impact on excessive daytime sleepiness and night-time sleep quality in Parkinson's disease patients. Depression is a common risk factor for both EDS and poor sleep quality in PD patients. More attention is needed for sleep disorders in male late-onset PD patients.
Article
Nutrition & Dietetics
Muhammed Tunc, Pinar Soysal, Ozge Pasin, Lee Smith, Masoud Rahmati, Veliye Yigitalp, Sevnaz Sahin, Moustapha Drame
Summary: The aim of this study was to investigate the relationship between serum magnesium levels and insomnia and excessive daytime sleepiness (EDS) in older adults. It found that hypomagnesemia was associated with a higher prevalence of EDS but not insomnia in older outpatients. Other health conditions such as hypertension and diabetes mellitus were also more common in the hypomagnesemia group. These findings suggest that hypomagnesemia should be considered when evaluating older adults with EDS.
Review
Clinical Neurology
Hanshu Liu, Jingwen Li, Xinyi Wang, Jinsha Huang, Tao Wang, Zhicheng Lin, Nian Xiong
Summary: Excessive daytime sleepiness is a common sleep disorder in Parkinson's disease, which has attracted attention due to its impact on quality of life, increased risk for accidents, and limited therapeutic options. This review summarizes the current research on the epidemiology of excessive daytime sleepiness in Parkinson's disease, explores the effects of commonly used drugs on excessive daytime sleepiness, and highlights the underlying mechanisms for its development. It also emphasizes the importance of identifying therapeutic targets for the development of novel interventions.
NATURE AND SCIENCE OF SLEEP
(2022)
Article
Critical Care Medicine
Jean-Louis Pepin, Ognian Georgiev, Rumen Tiholov, Valerie Attali, Johan Verbraecken, Bertien Buyse, Markku Partinen, Ingo Fietze, Georgi Belev, Dejan Dokic, Renaud Tamisier, Patrick Levy, Isabelle Lecomte, Jeanne-Marie Lecomte, Jean-Charles Schwartz, Yves Dauvilliers
Summary: In individuals with moderate to severe OSA adhering to CPAP treatment but experiencing residual EDS, Pitolisant significantly reduced daytime sleepiness and improved participant-reported outcomes and physician-reported disease severity. Adverse events, mainly headache and insomnia, were higher with Pitolisant compared to placebo, but no significant safety concerns were reported.
Article
Psychology, Clinical
K. S. Young, K. L. Purves, C. Hubel, M. R. Davies, K. N. Thompson, S. Bristow, G. Krebs, A. Danese, C. Hirsch, C. E. Parsons, E. Vassos, B. N. Adey, S. Bright, L. Hegemann, Y. T. Lee, G. Kalsi, D. Monssen, J. Mundy, A. J. Peel, C. Rayner, H. C. Rogers, A. Ter Kuile, C. Ward, K. York, Y. Lin, A. B. Palmos, U. Schmidt, D. Veale, T. R. Nicholson, T. A. Pollak, S. A. M. Stevelink, T. Moukhtarian, A. R. Martineau, H. Holt, B. Maughan, A. Al-Chalabi, K. Ray Chaudhuri, M. P. Richardson, J. R. Bradley, P. F. Chinnery, N. Kingston, S. Papadia, K. E. Stirrups, R. Linger, M. Hotopf, T. C. Eley, G. Breen
Summary: This study examines the impact of the COVID-19 pandemic on mental health and identifies key risk factors for worsening symptoms. The results show small decreases in depression and anxiety symptoms and increases in PTSD symptoms in prospective analyses. However, retrospective analyses demonstrate significant large increases in depression and anxiety symptoms, with 55% of participants reporting worsening mental health since the beginning of the pandemic. Worsening symptoms are associated with prior mental health diagnoses, female gender, young age, and unemployed/student status.
PSYCHOLOGICAL MEDICINE
(2023)
Review
Clinical Neurology
Valentina Leta, Lisa Klingelhoefer, Katherine Longardner, Marta Campagnolo, Hafize Cotur Levent, Federico Aureli, Vinod Metta, Roongroj Bhidayasiri, Guy Chung-Faye, Cristian Falup-Pecurariu, Fabrizio Stocchi, Peter Jenner, Tobias Warnecke, K. Ray Chaudhuri
Summary: Levodopa is the gold standard treatment for Parkinson's disease, but it often leads to motor and non-motor fluctuations. Gastrointestinal barriers, such as dysphagia, delayed gastric emptying, and gut dysbiosis, can affect levodopa absorption and response. Managing gastrointestinal dysfunction is crucial for optimizing levodopa therapy.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Patricia Lyra, Vanessa Machado, Silvia Rota, Kallol Ray Chaudhuri, Joao Botelho, Jose Joao Mendes
Summary: The development of neurodegenerative disorders, such as Parkinson's Disease, is closely linked to inflammation and dysbiosis. Understanding the mechanistic pathways of alpha-synucleinopathies and the impact of microbial dysbiosis on alpha-Syn can provide insights into the management and prevention of these conditions, with a focus on inflammatory mitigation and microbial balance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Clinical Neurology
K. Ray Chaudhuri, Valentina Leta, Kirsty Bannister, David J. J. Brooks, Per Svenningsson
Summary: In Parkinson disease (PD), some patients have non-motor symptoms that are related to abnormalities in noradrenergic function. Research suggests the existence of a noradrenergic subtype of PD, characterized by specific non-motor symptoms such as rapid eye movement sleep behavior disorder, pain, anxiety, and dysautonomia. Understanding this subtype could lead to personalized treatments for PD.
NATURE REVIEWS NEUROLOGY
(2023)
Article
Behavioral Sciences
Sara Pisani, Brandon Gunasekera, Yining Lu, Miriam Vignando, Dominic Ffytche, Dag Aarsland, K. Ray Chaudhuri, Clive Ballard, Jee-Young Lee, Yu Kyeong Kim, Latha Velayudhan, Sagnik Bhattacharyya
Summary: This study conducted a meta-analysis of MRI studies to explore the neuroanatomical alterations underlying psychosis in Parkinson's Disease (PDP). The results revealed widespread grey matter volume loss in the parieto-temporo-occipital regions of PDP patients, which was associated with the expression of serotonergic receptor genes (5-HT1a and 5-HT2a), but not dopaminergic receptors.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2023)
Article
Neurosciences
K. Ray Chaudhuri, Norbert Kovacs, Francesco E. Pontieri, Jason Aldred, Paul Bourgeois, Thomas L. Davis, Esther Cubo, Marieta Anca-Herschkovitsch, Robert Iansek, Mustafa S. Siddiqui, Mihaela Simu, Lars Bergmann, Mayra Ballina, Pavnit Kukreja, Omar Ladhani, Jia Jia, David G. Standaert
Summary: The DUOGLOBE study demonstrates long-term reductions in motor and non-motor symptoms in patients with aPD treated with LCIG in a real-world setting.
JOURNAL OF PARKINSONS DISEASE
(2023)
Review
Clinical Neurology
Ali Shojaie, Silvia Rota, Ahmad Al Khleifat, K. Ray Chaudhuri, Ammar Al-Chalabi
Summary: Amyotrophic lateral sclerosis and Parkinson's disease, both neurodegenerative diseases affecting the motor system, are now known to also impact non-motor pathways. Non-motor symptoms play a significant role in determining the quality of life in Parkinson's disease, and there is growing interest in understanding the extent and role of these symptoms in amyotrophic lateral sclerosis. Hence, we conducted a review to summarize the current knowledge of non-motor symptoms in amyotrophic lateral sclerosis based on insights from Parkinson's disease.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
(2023)
Review
Health Care Sciences & Services
Vinod Metta, Guy Chung-Faye, Hani T. S. Benamer, Rukmini Mrudula, Vinay Goyal, Cristian Falup-Pecurariu, Neha Muralidharan, Desh Deepak, Mohammed Abdulraheem, Rupam Borgohain, Kallol Ray Chaudhuri
Summary: Parkinson's disease is a chronic and progressive neurological disorder, ranking as the second most common neurodegenerative condition. This study highlights the prevalence, pathophysiology, and evidence-based treatment strategies for three commonly overlooked symptoms in Parkinson's disease: hiccups, hypersalivation, and hallucinations. Early recognition and treatment are crucial for improving the quality of life for patients.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Clinical Neurology
Glynn Harrison-Jones, Xiaocong Li Marston, Francesca Morgante, K. Ray Chaudhuri, Guillermo Castilla-Fernandez, Valentina Di Foggia
Summary: This study found that initiating COMT inhibition with opicapone is likely to decrease healthcare resource utilization compared to initiation with entacapone in people with Parkinson's disease.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Ali Shojaie, Ahmad Al Khleifat, Sarah Opie-Martin, Payam Sarraf, Ammar Al-Chalabi
Summary: This study aimed to examine the nature and extent of non-motor symptoms in ALS. Through an online questionnaire and sharing on social media platforms, a total of 1018 responses were received, including 506 people with ALS and 421 unaffected individuals. The study found that people with ALS were more likely to report autonomic symptoms, pain, and psychiatric symptoms, which significantly impacted their quality of life. Therefore, the identification and management of non-motor symptoms are crucial in the clinical care of ALS patients.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
(2023)
Review
Clinical Neurology
Kausar Raheel, Gemma Deegan, Irene Di Giulio, Diana Cash, Katarina Ilic, Valentina Gnoni, K. Ray Chaudhuri, Panagis Drakatos, Rosalyn Moran, Ivana Rosenzweig
Summary: Past research suggests that there are more cases and severe clinical manifestations of alpha-synucleinopathies in men, indicating potential neuroprotective properties of female sex hormones, especially estrogen. However, the underlying mechanisms of this effect are not well understood. This study aimed to systematically review and critically assess the current evidence on sex and gender differences in alpha-synucleinopathies.
FRONTIERS IN NEUROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Iro Boura, Mubasher A. Qamar, Francesco Daddoveri, Valentina Leta, Karolina Poplawska-Domaszewicz, Cristian Falup-Pecurariu, K. Ray Chaudhuri
Summary: This article reviews the research on the relationship between COVID-19 and PD over the past three years, finding that COVID-19 may worsen PD symptoms and increase mortality in PD patients. Additionally, new-onset parkinsonism or PD following COVID-19 infection has been reported, although this link remains hypothetical.
Article
Clinical Neurology
Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung
Summary: This article reports the results of a 52-week open-label registrational trial that evaluated the safety, tolerability, and efficacy of 24-hour foslevodopa/foscarbidopa continuous subcutaneous infusion in patients with advanced Parkinson's disease. The findings suggest that this treatment has the potential to improve motor control, sleep quality, and quality of life in patients with Parkinson's disease.
NEUROLOGY AND THERAPY
(2023)
Editorial Material
Clinical Neurology
K. Ray Chaudhuri, Lucia Batzu
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Review
Clinical Neurology
Nicole Campese, Bianca Calio, Fabian Leys, Lalit Kaltenbach, Georg Goebel, Julia Wanschitz, Andreas Schlager, Laura Zamarian, Kirsty Bannister, Ray K. Chaudhuri, Anette Schrag, Roberta Granata, Stefan Kiechl, Werner Poewe, Klaus Seppi, Gregor Wenning, Alessandra Fanciulli
Summary: This study aimed to assess the prevalence, characteristics, and risk factors for pain in individuals with multiple system atrophy (MSA). The results showed that pain is a frequent but under-recognized and undertreated feature of MSA. Further research is needed to improve pain detection and treatment in MSA.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)